[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Uptake Medical Technology, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100325232","vapor-ablation-for-localized-cancer-lesions-100325232",false,"NCT03514329","Vapor Ablation for Localized Cancer Lesions","Vapor Ablation for Localized Cancer Lesions of the Lung - A Clinical Feasibility Definitive Treatment Study","VAPORIZED","Inclusion Criteria:\n\n1. Age: ≥ 18 years old\n2. Patient has been recommended for ablation or recommended for an alternative to surgery\n3. Non-small cell lung cancer tumor(s) ≤ 2cm (T1aN0, T1bN0) OR Metastatic lung tumor(s) ≤ 2cm\n4. Microscopic proof of malignancy obtained\n5. Location of tumor:\n\n   1. In periphery of lung (outermost 1\u002F3)\n   2. Maximum of three vapor ablation applications would target entire margin according to the vapor ablation plan\n6. Signed patient informed consent\n\nExclusion Criteria:\n\n1. Centralized tumor (abutting main stem bronchus, main pulmonary artery branches, esophagus, or trachea)\n2. Carcinoid lung tumors\n3. Tumor is associated with atelectasis or obstructive pneumonitis or pleural effusion\n4. Pulmonary function tests (PFTs): post-bronchodilator forced expired volume in one second (FEV1) \\\u003C20% predicted, diffusing capacity of the lung for carbon monoxide (DLCO)\\\u003C20% predicted\n5. Requirement for supplemental oxygen (includes at rest or during exercise)\n6. Hospitalization for cardiac disease within the preceding 6 months\n7. Liver enzymes (ALP, ALT, AST) or total bilirubin \\> 1.5 upper limit of normal (ULN)\n8. Serum creatinine \\> 2 mg\u002Fdl\n9. Recent infection (within 30 days)\n10. Currently receiving immunosuppressive medication or prednisone \\> 10 mg\u002Fday (or equivalent)\n11. Pre-existing implants within the airways that impede navigation to the target lesion\n12. Pregnant or breastfeeding women and those of childbearing potential who are not practicing a reliable form of contraception.\n13. Disorder of coagulation, history of severe hemoptysis, or receiving anticoagulant medication. Antiplatelet medication is permitted provided that the medication can be held a minimum of 7 days prior to the procedure and 10 days post-procedure.\n14. Any condition that in the opinion of the investigator or reviewer may interfere with the safety of the patient or evaluation of the study objectives\n15. Any tumor characteristic that in the opinion of the investigator or reviewers may interfere with the safety of the patient or evaluation of the study objectives.","ALL","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is a prospective, single-arm, multi-center, pilot trial of Bronchoscopic Thermal Vapor Ablation for Lung Cancer (BTVA-C) in patients with primary lung cancer or metastatic cancer in the lung. Patients who have consented to participate in this study (enrolled) will be subject to eligibility screening and baseline assessments, prior to undergoing the BTVA-C procedure. Only patients that meet all of the inclusion criteria and none of the exclusion criteria will receive vapor ablation treatment.\n\nPatients will be followed for up to 12 months.",[27,28,29],"Non Small Cell Lung Cancer","Metastatic Lung Cancer","Lung Cancer",[27,28,29,31,32],"Vapor Ablation","BTVA","NOT_YET_RECRUITING","2025-02-24",{"date":36,"type":37},"2025-02-27","ACTUAL",{"date":39,"type":21},"2026-09-01",{"date":41,"type":21},"2028-06-30",{"name":43,"class":44},"Uptake Medical Technology, Inc.","INDUSTRY",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100310210","post-market-btva-registry-100310210","NCT03318406","Post-Market BTVA Registry","Post-Market Registry for Patients With Emphysema Treated With BTVA","Inclusion Criteria:\n\n1. Patients will have heterogeneous emphysema, as evidenced by high-resolution computed tomography (HRCT) demonstrating a heterogeneity index \\> or equal to 1.2 in at least one segment to be treated\n2. Patients must be \\> or equal to 18 years of age\n3. Patients are required to provide informed consent prior to inclusion in the Registry\n\nExclusion Criteria:\n\n1. FEV1 \\\u003C 20% predicted\n2. DLCO \\\u003C 20% predicted\n3. Inability to walk \\> 140 meters in 6 minutes (6MWD) following optimized medical management\n4. Unstable COPD (any of the following):\n\n   1. \\> 3 COPD related hospitalizations requiring antibiotics in past 12 months\n   2. COPD related hospitalization in past 3 months\n   3. daily use of systemic steroids, i.e. \\> 5 mg prednisolone\n5. Concomitant illnesses or medications that would pose a significant increased risk for complications following treatment with InterVapor. Examples of particular relevance include: immune system disorders, immunosuppressant medications of clinical relevance, bleeding disorders and unstable cardiovascular conditions, history of asthma or alpha-1 antitrypsin deficiency\n6. Newly prescribed morphine derivatives within the last 4 weeks\n7. Pregnant or breastfeeding\n8. Highly diseased lower lobes (tissue to air ratio of \\\u003C11%)\n9. Bacterial infection or symptoms indicative of active infection (i.e., fever, elevated white blood cell count)\n10. Presence of single large bulla (defined as \\> 1\u002F3 volume of lobe) or a paraseptal distribution of emphysema in the treated lobe\n11. Recent respiratory infections or COPD exacerbation in preceding 6 weeks -",{"count":53,"type":21},300,"5 Years","OBSERVATIONAL","Bronchoscopic thermal vapor ablation using Uptake Medical Technology Inc.'s InterVapor System is indicated for treatment of patients with heterogeneous upper lobe emphysema. This study is a retrospective and prospective, observational, multi-center, post-market registry of patients prescribed InterVapor. The primary objective of the Registry is to describe the long-term impact of InterVapor treatment on patient quality of life (QOL) in a real-world setting. After InterVapor treatment, patients will be followed for 5 years as per the standard of care and safety and efficacy data (quality of life, pulmonary function, exercise capacity) collected as part of the registry.",[58],"Emphysema or COPD",[60,61,62,32],"registry","vapor ablation","InterVapor","RECRUITING","2025-01-25",{"date":66,"type":37},"2025-01-28",{"date":68,"type":37},"2018-03-22",{"date":70,"type":21},"2030-12-01",{"name":43,"class":44},20,""]